Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000797588 | SCV000937152 | pathogenic | Neurofibromatosis, type 1 | 2018-11-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ile1971Lysfs*14) in the NF1 gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in an individual affected with neurofibromatosis type 1 (PMID: 21354044). Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002352337 | SCV002652585 | pathogenic | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2020-08-20 | criteria provided, single submitter | clinical testing | The c.5908_5915delTCTATTCA pathogenic mutation, located in coding exon 39 of the NF1 gene, results from a deletion of 8 nucleotides at nucleotide positions 5908 to 5915, causing a translational frameshift with a predicted alternate stop codon (p.I1971Kfs*14). This mutation has been reported in an individual meeting NIH diagnostic criteria for neurofibromatosis type 1 (Valero M et al. J Mol Diagn 2011 Mar;13(2):113-22). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |